Advancements in the treatment of pain: not all opioids are the same
Published: May 20, 2024
Abstract Views: 1369
PDF: 210
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
In the heated discourse about the pros and cons of opioids, it is not uncommon to have them discussed as if there are no significant differences among them (except perhaps on the basis of potency, viz., the piperidine fentanyl and its structural analogs such as alfentanil, carfentanil, sufentanil, etc.). It thus seems timely and appropriate to reassess this perception. There are at least three “atypical” opioids approved for clinical use, and another in development, that in one way or another display a more favorable clinical profile than do the “typical” opioids such as morphine, oxycodone, etc.
Altmetrics
Downloads
Download data is not yet available.
Citations
Lischka A, Lassuthova P, Cakar A, et al. Genetic pain loss disorders. Nat Rev Dis Primers 2022;8:41. DOI: https://doi.org/10.1038/s41572-022-00365-7
Bodnar RJ. Endogenous opiates and behavior: 2020. Peptides 2022;151:170752. DOI: https://doi.org/10.1016/j.peptides.2022.170752
Paul AK, Smith CM, Rahmatullah M, et al. Opioid analgesia and opioid-induced adverse effects: a review. Pharmaceuticals (Basel) 2021;14:1091. DOI: https://doi.org/10.3390/ph14111091
Stein C. Opioid receptors. Annu Rev Med 2016;67:433-51. DOI: https://doi.org/10.1146/annurev-med-062613-093100
Al-Hasani R, Bruchas MR. Molecular mechanisms of opioid receptor-dependent signaling and behavior. Anesthesiology 2011;115:1363-81. DOI: https://doi.org/10.1097/ALN.0b013e318238bba6
Spetea M, Schmidhammer H. Opioids and their receptors: present and emerging concepts in opioid drug discovery. Molecules 2020;25:5658. DOI: https://doi.org/10.3390/molecules25235658
Moayedi M, Davis KD. Theories of pain: from specificity to gate control. J Neurophysiol 2013;109:5-12. DOI: https://doi.org/10.1152/jn.00457.2012
Nijs J, George SZ, Clauw DJ, et al. Central sensitisation in chronic pain conditions: latest discoveries and their potential for precision medicine. Lancet Rheumatol 2021;3:e383-92. DOI: https://doi.org/10.1016/S2665-9913(21)00032-1
Pak DJ, Yong RJ, Kaye AD, Urman RD. Chronification of pain: mechanisms, current understanding, and clinical implications. Curr Pain Headache Rep 2018;22:9. DOI: https://doi.org/10.1007/s11916-018-0666-8
Mauceri D. Role of epigenetic mechanisms in chronic pain. Cells 2022;11:2613. DOI: https://doi.org/10.3390/cells11162613
Guo R, Chen Lh, Xing C, Liu T. Pain regulation by gut microbiota: molecular mechanisms and therapeutic potential. Br J Anaesth 2019;123:637-54. DOI: https://doi.org/10.1016/j.bja.2019.07.026
Vargas-Schaffer G. Is the who analgesic ladder still valid? Twenty-four years of experience. Can Fam Physician 2010;56:514-7, e202-5.
Kim SJ,Seo JT. Selection of analgesics for the management of acute and postoperative dental pain: a mini-review. J Periodontal Implant Sci 2020;50:68-73. DOI: https://doi.org/10.5051/jpis.2020.50.2.68
Middleton C. Understanding the physiological effects of unrelieved pain. Nurs Times 2003;99:28-31.
Staud R, Robinson ME, Vierck CJ, Jr., Price DD. Diffuse noxious inhibitory controls (dnic) attenuate temporal summation of second pain in normal males but not in normal females or fibromyalgia patients. Pain 2003;101:167-74. DOI: https://doi.org/10.1016/S0304-3959(02)00325-1
Millan MJ. Descending control of pain. Prog Neurobiol 2002;66:355-474. DOI: https://doi.org/10.1016/S0301-0082(02)00009-6
Somogyi AA, Musolino ST, Barratt DT. New pharmacological perspectives and therapeutic options for opioids: differences matter. Anaesth Intensive Care 2022;50:127-40. DOI: https://doi.org/10.1177/0310057X211063891
Gudin J, Fudin J. A narrative pharmacological review of buprenorphine: a unique opioid for the treatment of chronic pain. Pain Ther 2020;9:41-54. DOI: https://doi.org/10.1007/s40122-019-00143-6
Reeves RR, Burke RS. Tramadol: basic pharmacology and emerging concepts. Drugs Today (Barc) 2008;44:827-36. DOI: https://doi.org/10.1358/dot.2008.44.11.1308916
Romualdi P, Grilli M, Canonico PL, Collino M, Dickenson AH. Pharmacological rationale for tapentadol therapy: a review of new evidence. J Pain Res 2019;12:1513-20. DOI: https://doi.org/10.2147/JPR.S190160
Ziemichod W, Kotlinska J, Gibula-Tarlowska E, et al. Cebranopadol as a novel promising agent for the treatment of pain. Molecules 2022;27:3987. DOI: https://doi.org/10.3390/molecules27133987
Terlinden R, Kogel BY, Englberger W, Tzschentke TM. In vitro and in vivo characterization of tapentadol metabolites. Methods Find Exp Clin Pharmacol 2010;32:31-8. DOI: https://doi.org/10.1358/mf.2010.32.1.1434165
Tzschentke TM, Christoph T, Kogel B, et al. (-)-(1r,2r)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol hcl): a novel mu-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties. J Pharmacol Exp Ther 2007;323:265-76. DOI: https://doi.org/10.1124/jpet.107.126052
Schroder W, Tzschentke TM, Terlinden R, et al. Synergistic interaction between the two mechanisms of action of tapentadol in analgesia. J Pharmacol Exp Ther 2011;337:312-20. DOI: https://doi.org/10.1124/jpet.110.175042
Cowan A, Raffa RB, Tallarida CS, et al. Lack of synergistic interaction between the two mechanisms of action of tapentadol in gastrointestinal transit. Eur J Pain 2014;18:1148-56. DOI: https://doi.org/10.1002/j.1532-2149.2014.00461.x
Freo U, Romualdi P, Kress G. Tapentadol for neuropathic pain: a review of clinical studies. J Pain Res 2019;12:1537-51. DOI: https://doi.org/10.2147/JPR.S190162
How to Cite
1.
Raffa RB. Advancements in the treatment of pain: not all opioids are the same. Adv Health Res [Internet]. 2024 May 20 [cited 2025 Apr. 30];1(1). Available from: https://www.ahr-journal.org/site/article/view/3
Copyright (c) 2024 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.